Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMML

Inclusion Criteria: 1. MDS and CMML subjects with higher risk; 2. Age ≥ 18 years old; 3. Eastern Cooperative Oncology Group score of 0\~2; 4. Not suitable for or refuse to receive hematopoietic stem cell transplant(HSCT); 5. Subjects should take effective contraceptive measures 6. Must sign the Informed Consent Form (ICF), and be able to follow all study procedures. Exclusion Criteria: 1. Prior exposure to anti-TIM-3 therapy at any time 2. Previous HSCT 3. Live vaccine administered within 4 weeks prior to start of treatment 4. Current use or use within 7 days prior to start of treatment of systemic steroid therapy (\> 10 mg/day prednisone or equivalent) or any immunosuppressive therapy. Topical, inhaled, nasal, ophthalmic steroids are allowed. Other protocol-defined Inclusion/Exclusion may apply.